Cosmos Health Inks 5-Year Deal to Commercialize DIABIT-IS X in Greece
COSM sits 86% above its 52-week low of $0.162.
Summary
Cosmos Health signed a five-year agreement with Libytec to commercialize its prescription drug DIABIT-IS X in Greece, with access expected through the national health insurance system. This marks a concrete step in the company's prescription medicine strategy, providing a defined market pathway for a key product. The deal follows a series of ambitious announcements—including $200M revenue guidance and European Investment Bank discussions—but comes against a backdrop of going concern warnings, widening losses, and heavy dilution. The partnership could generate recurring revenue, though the financial terms and market size remain undisclosed. Given the company's $18.7M market cap and cash burn, any new commercial traction is material, but execution risk is high.
At the time of this announcement, COSM was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.